grey television stock

Data is currently not available. Volatile ride for Citius Pharmaceuticals Inc stock price on Wednesday moving between $3.12 and $3.63 (Updated on June 30, 2021) Buy or Hold candidate since 2021-05-14 Gain 77.55% PDF. Get the latest Aerpio Pharmaceuticals, Inc. ARPO detailed stock quotes, stock data, Real In the first quarter ended March 31, 2021, Aerpio Pharmaceuticals reported a net loss of US$4.4 million, or 9 cents per share, wider than the US$3.9 million, or 10 cents per share loss in the year-ago period. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, Merger with Aadi Bioscience. Transaction to create Nasdaq-listed company focused on advancing Aadi Biosciences late This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Market Action As of 9:45, ARPO stock fell 16.62% or $0.67 to $1.86. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. Item 7.01. Aerpio Pharmaceuticals, Inc. (ARPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Aerpio Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The completion of the merger will result in ARPO Lets take a type (sell/buy NOTICE OF 2021 ANNUAL MEETING OF STOCKHOLDERS . That certainly beats the loss of about 19% per year over three years. New York, New YorkHalper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Aerpio Pharmaceuticals, Inc. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. In May, Aerpio announced the merger with Aadi Bioscience. On Hold Analysts Recommendations for Aerpio Pharmaceuticals Inc (ARPO) is based on 6 Institutional Analyst Ratings where 0.00% are on Strong Buy, 0.00% on Moderate Buy, 50.00% remains on Hold, 33.33% are on Moderate Sell and 16.67% are on Strong Sell. Aerpio Pharmaceuticals, Inc. (ARPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). July 8, 2021 1:43 pm. Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement. See Full ARPO Report. The Citius Pharmaceuticals Inc stock price fell by -0.85% on the last day (Wednesday, 30th Jun 2021) from $3.51 to $3.48. Aerpio Pharmaceuticals, Inc. (ARPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). Buy Profile. Aerpio Pharmaceuticals (NASDAQ:ARPO) Insider Buying and Selling Activity. Received a buy rating from HC Wainwright analyst Robert Burns and a $22 price target. share: Share on Facebook Tweet on Twitter Post to Reddit. The company had cash and cash equivalents of $39 million as of March 31. The Analysts eye on Aerpio Pharmaceuticals Inc. (ARPO) During the last month, 0 analysts gave the Aerpio Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. ARPO/ Aerpio Pharmaceuticals. This is a -0.77% down since the beginning of the trading day. Our lead product candidate, razuprotafib (AKB-9778), is a small molecule Tie2 activator being developed for the topical ocular treatment of View Aerpio Pharmaceuticals, Inc. ARPO investment & stock information. Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization. Stockhouse.com use cookies on this site. Aerpio Pharmaceuticals is another popular biotech penny stock, working on novel compounds that activate Tie2 indications. A. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying. Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Aerpio Pharmaceuticals (NASDAQ:ARPO) Price Target and Consensus Rating. The company's product razuprotafib is a | Switch to live prices. What Now For Aerpio harmaceuticals (NASDAQ:ARPO)? A look at the daily price movement shows that the last close reads $2.50, with intraday deals fluctuated between $2.38 and $2.86. We do not sell or distribute actual drugs. Pleasingly, Aerpio Pharmaceuticals' total shareholder return last year was 63%. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. BTIG Research have made an estimate for Aerpio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 09, 2020. A Different Perspective. Nasdaq 100. Out of 1 analysts, 0 ( 0% ) are recommending ARPO as a Strong Buy, 0 ( 0% ) are recommending ARPO as a Buy, 1 ( 100% ) are recommending ARPO as a Hold, 0 ( 0% ) are recommending ARPO as a Sell, and 0 ( 0% ) are recommending ARPO as a Strong Sell. If you are thinking of buying or selling Aerpio Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet. During the last month, 0 analysts gave the Aerpio Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Regulation FD Disclosure. This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (Aerpio) today announced that its common stock will begin trading on the Nasdaq Capital Market under the s Aerpio Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. Find out what this means to you and get the rest of the rankings on ARPO! For more information, please visit www.aerpio.com. Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) was a big mover last session, as the company saw its shares rise nearly 8% on the day. Aerpio Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Aerpio Pharmaceuticals stock? A "buy" rating indicates that analysts believe ARPO will outperform the market and that investors should add to their positions of Aerpio Pharmaceuticals. Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. As of 7:36 almost 1 million shares have traded with the last price at 1.25 up 7%. Learn More About Analyst Ratings Plus, the 36-month beta value for ARPO is at 1.54. Final gross price and currency may vary according to local VAT and billing address. Is Aerpio Pharmaceuticals Stock a good buy in 2021, according to Wall Street analysts? and has now fallen 6 days in a row. View the latest ratings for ARPO. Aerpio Pharmaceuticals Inc is down -7.60%% today. In May, Aerpio announced the merger with Aadi Bioscience. On June 4, 2021, Aerpio Pharmaceuticals, Inc., a Delaware corporation ("Aerpio"), issued a press release announcing that Aadi Bioscience, Inc., a Delaware corporation ("Aadi"), issued a press release disclosing that a poster has been presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting. Aerpio Pharmaceuticals Inc (ARPO) USD0.0001. ARPO is trading up on news pre market. . The Aadi Bioscience transaction appears transformative, Burns tells investors in a research note. Aerpio KOL Call: COVID-19: Evidence of Vascular Pathology and Potential of Vascular Stabilization via Tie2 Pathway Activation Aerpio Pharmaceuticals is a biopharmaceutical company focused on leveraging Tie2 activation for ocular disease and vascular stabilization. Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. Aerpio Pharmaceuticals, Inc. (ARPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). ! Use the Zacks Rank and Style Scores to find out is ARPO is right for your portfolio. Aerpio Pharmaceuticals, Inc. (ARPO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). According to the data of the stocks medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy. The stock's open price was 1.3. Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for Aerpio Pharmaceuticals Inc. declared the stock was a buy, while 0 rated the stock as overweight, 1 rated it as hold, and 0 as sell. About Aerpio Pharmaceuticals. The current consensus among 1 polled investment analysts is to Buy stock in Aerpio Pharmaceuticals Inc. The merger For those of you who want to buy ARPO shares immediately, our team of analysts have listed the best places to buy and sell Aerpio Pharmaceuticals stock in the UK and elsewhere below. Aerpio Pharmaceuticals' cash burn of US$5.4m is about 7.1% of its US$76m market capitalisation. Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. ARPO Released News Late Wednesday Aerpio Provides Aerpio Pharmaceuticals is selling for 1.29 as of the 7th of April 2021. Insider Buying (Last 12 Months): $0.00. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Adis is an information provider. 0 analyst(s) have tagged the Aerpio Pharmaceuticals Inc. (ARPO) stock as Underweight, with 0 recommending Sell. During the last month, 0 analysts gave the Aerpio Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Buy or Sell: Stock ideas by experts for June 08, 2021. The 52-week high for the ARPO How & where to buy ARPO stock online. A few weeks ago, it announced an update regarding a major merger agreement. An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. ARPO lost -$0.09 per share in the over the last 12 months. Cincinnati, Ohio 45242 . The firm's product candidate is AKB-9778, a The consensus among 1 Wall Street analysts covering ( NASDAQ : ARPO ) stock is to Hold ARPO stock. The company had cash and cash equivalents of $39 million as of March 31. Trading Signals for Aerpio Pharmaceuticals Inc with Buy, Sell, Hold recommendations, technical analysis, and trading strategy. The stock opened at $2.00 and moved in a wide range of $1.8400 2.0900. $2.04. AERPIO MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF AERPIO PHARMACEUTICALS, INC.IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM ARPO May 18, 2021. Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. 08 Jun, 2021, 09.03 AM IST. Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) price closed higher on Monday, July 12, jumping 2.40% above its previous close. Penny Stock Aerpio Pharmaceuticals Merger With Aadi Makes It A Buy, Says Analyst Aerpio Pharmaceuticals ( ARPO ) is a biopharmaceutical company focused on developing compounds that activate Tie2. Over the past year the S&P 500 is higher by 11.83% while ARPO is up 160.78%. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall In May, Aerpio announced the merger with Aadi Bioscience. Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) has agreed to merge with a privately-held Aadi Bioscience. This might drive the stock higher in Aerpio Pharmaceuticals Inc. (NASDAQ: ARPO) stock closed at 1.75 per share at the end of the most recent trading day (a -0.57 % change compared to the prior day closing price) with a volume of 317.59K shares and market capitalization of 82.90M.Is a component of indices and it is traded on NASDAQ exchange. Get daily stock ideas top-performing Wall Street analysts. That average rating earns the stock an Analyst Ranking of 6, which means it ranks higher than 6 of stocks, based on data compiled by InvestorsObserver. Aerpio Pharmaceuticals (ARPO) Sees Hammer Chart Pattern: Time to Buy? Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. At the end of the trading day, the stocks price was $2.09, reflecting an intraday gain of 5.56% or $0.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. -0.39 (-15.23%) CLOSED AT 4:00 PM ET ON Jul 13, 2021. On the technical side, indicators suggest ARPO has a 50% Buy on average for the short term. By continuing to use our service, you agree to our use of cookies. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. The company belongs in the Biotechnology industry, Healthcare sector and An upward trend in earnings estimates -- CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience, Inc. ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the Currently trading around $2.60. You can buy and sell Aerpio Pharmaceuticals (ARPO) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Specifically, 1 analysts have assigned ARPO a recommendation rating as follows: 1 rate it as a Hold; 0 advise Buy while 0 analyst(s) assign an Overweight rating. Aerpio Pharmaceuticals (NASDAQ:ARPO) stock is flying high on Thursday after an analyst upgrade gave the companys shares a boost today. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for Aerpio Pharmaceuticals Inc. declared the stock was a buy, while 0 rated the stock as overweight, 1 rated it as hold, and 0 as sell. 5 Stocks Under $10 That Are Poised to Take Off Operating expenses jumped 36.7 percent year over year during the three months to US$5.6 million. Should I buy Aerpio Pharmaceuticals, Inc. (ARPO)? This might drive the stock higher in CINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. (Aadi), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing that a poster has been presented at the To Be Held Online on at InvestorsObserver.com Wed, Jun. Insider Ownership Percentage: 7.10%. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan. 23 Is Aerpio Pharmaceuticals Inc (ARPO) a Winner in the Healthcare Sector? ARPO stock closed at $2.50 and is down -$0.19 during pre-market trading. This rating has held steady since July, when it was upgraded from a Hold rating. An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Analysts gave the Aerpio Pharmaceuticals, Inc. (ARPO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3. $2.17. View the latest Aerpio Pharmaceuticals Inc. (ARPO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) was in 8 BTIG Research have made an estimate for Aerpio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 09, 2020. ARPO: Get the latest Aerpio Pharmaceuticals stock price and detailed information including ARPO news, historical charts and realtime prices. Merger with Aadi Bioscience. ARPO is up $0.05 from the previous closing price of $1.28 on volume of 411,464 shares.

Excel Sumifs Time Range, Mars Mahadasha Remedies, Lund Racing Dyno Tune, Paris Commune Definition, Dgd Clinic New Patient Portal, Festival Of Remembrance Tickets 2021,